Killian Meara

PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.

LEO Pharma reveals promising phase 2b trial results for temtokibart, a treatment targeting moderate to severe atopic dermatitis effectively.

Adhering to a Mediterranean diet and incorporating omega-3 supplements led to noticeable improvements in acne severity, reducing both inflammatory and non-inflammatory lesions in patients.

The most significant independent predictors of adherence to dermatology follow-up appointments were younger age and previous outpatient visits.

In ethnic and racial minority populations, more than 12,000 standard skin cancer screenings would be done to identify 1 case of melanoma, according to a recent study.

The Act4Biosimilars Action Plan aims to highlight key challenges preventing patient access to biosimilars and outline steps to help overcome them.